| scholarly article | Q13442814 |
| P50 | author | Eleftherios Mylonakis | Q56769876 |
| P2093 | author name string | Beth Burgwyn Fuchs | |
| Juliana Campos Junqueira | |||
| Patrícia Pimentel de Barros | |||
| Rodnei Dennis Rossoni | |||
| Rebeca Previate Medina | |||
| Dulce Helena Siqueira Silva | |||
| Iatã do Carmo Mendonça | |||
| P2860 | cites work | Probiotics Prevent Candida Colonization and Invasive Fungal Sepsis in Preterm Neonates: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Q28072647 |
| Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species | Q28829671 | ||
| Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans | Q33369708 | ||
| Candida albicans-epithelial interactions: dissecting the roles of active penetration, induced endocytosis and host factors on the infection process | Q34273787 | ||
| Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens | Q34299911 | ||
| Development of probiotic formulations for oral candidiasis prevention: Gellan gum as a carrier to deliver Lactobacillus paracasei 28.4. | Q91609932 | ||
| Candida albicans Biofilms Are Generally Devoid of Persister Cells | Q91726590 | ||
| Novel Therapies for Biofilm-Based Candida spp. Infections | Q92011547 | ||
| Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris | Q92071802 | ||
| Candida spp./Bacteria Mixed Biofilms | Q92156552 | ||
| The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant Staphylococcus aureus | Q92404364 | ||
| Administration of a Postbiotic Causes Immunomodulatory Responses in Broiler Gut and Reduces Disease Pathogenesis Following Challenge | Q92703098 | ||
| Botryane terpenoids produced by Nemania bipapillata, an endophytic fungus isolated from red alga Asparagopsis taxiformis - Falkenbergia stage | Q92833110 | ||
| Postbiotics produced at laboratory and industrial level as potential functional food ingredients with the capacity to protect mice against Salmonella infection | Q93020706 | ||
| Definition of Opportunistic Infections in Immunocompromised Children on the Basis of Etiologies and Clinical Features: A Summary for Practical Purposes | Q93050011 | ||
| World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. | Q55056247 | ||
| Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. | Q55689919 | ||
| Candida auris: An emerging drug resistant yeast – A mini-review | Q59286513 | ||
| Recent Advances in the Use of Galleria mellonella Model to Study Immune Responses against Human Pathogens | Q60143650 | ||
| Lactobacillus species increase the survival of Galleria mellonella infected with Candida albicans and non–albicans Candida clinical isolates | Q60146746 | ||
| What Have We Learned About Its Mechanisms of Pathogenicity? | Q60958254 | ||
| Candida auris: An emerging pathogen "incognito"? | Q64068234 | ||
| A Novel Postbiotic From GG With a Beneficial Effect on Intestinal Barrier Function | Q64092990 | ||
| Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations | Q70409691 | ||
| Promising Alternative Therapeutics for Oral Candidiasis | Q88935891 | ||
| Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? | Q89510130 | ||
| Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond | Q90228845 | ||
| Multidrug-resistant Candida auris: an epidemiological review | Q90829411 | ||
| Can Postbiotics Represent a New Strategy for NEC? | Q91104364 | ||
| Heat-killed Lactobacillus reuteri and cell-free culture supernatant have similar effects to viable probiotics during interaction with Porphyromonas gingivalis | Q91136219 | ||
| Effects of surface pre-reacted glass-ionomer (S-PRG) eluate on Candida spp.: antifungal activity, anti-biofilm properties, and protective effects on Galleria mellonella against C. albicans infection | Q91224672 | ||
| Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. | Q34418447 | ||
| Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
| Mode of action of membrane active antimicrobial peptides | Q35030295 | ||
| Understanding biofilm resistance to antibacterial agents | Q35058558 | ||
| Novel strategies to fight Candida species infection. | Q35406737 | ||
| Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. | Q35745822 | ||
| Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. | Q35984512 | ||
| Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella. | Q36155002 | ||
| Lactobacillus paracasei modulates the immune system of Galleria mellonella and protects against Candida albicans infection | Q36299538 | ||
| Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome | Q36347301 | ||
| Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. | Q37889385 | ||
| Candida albicans dimorphism as a therapeutic target | Q37965698 | ||
| Postbiotics: what else? | Q38070062 | ||
| Postbiotic activities of lactobacilli-derived factors | Q38257723 | ||
| Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing | Q38686917 | ||
| Probiotics as Antifungals in Mucosal Candidiasis. | Q38716578 | ||
| Immunity of the greater wax moth Galleria mellonella | Q38723721 | ||
| The role of probiotics in prevention of oral diseases | Q38946358 | ||
| Candida albicans biofilms produce antifungal-tolerant persister cells | Q39077924 | ||
| Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. | Q39092336 | ||
| Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study | Q39242043 | ||
| Probiotic lactobacilli inhibit early stages of Candida albicans biofilm development by reducing their growth, cell adhesion, and filamentation. | Q39844093 | ||
| Analysis of the early cellular and humoral responses of Galleria mellonella larvae to infection by Candida albicans | Q40066549 | ||
| Galleria mellonella as an in vivo model for assessing the protective activity of probiotics against gastrointestinal bacterial pathogens | Q40267485 | ||
| Lactobacillus rhamnosus inhibits Candida albicans virulence factors in vitro and modulates immune system in Galleria mellonella | Q40510505 | ||
| Vertical stratification of matrix production is essential for physical integrity and architecture of macrocolony biofilms of Escherichia coli | Q41033906 | ||
| Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species | Q41991016 | ||
| Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis | Q41999751 | ||
| Dose-dependent cellular and humoral responses in Galleria mellonella larvae following beta-glucan inoculation. | Q42023130 | ||
| Fluctuations in haemocyte density and microbial load may be used as indicators of fungal pathogenicity in larvae of Galleria mellonella. | Q42045928 | ||
| Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars | Q45016433 | ||
| Candida auris: An Emerging Fungal Pathogen | Q46255772 | ||
| Fluconazole Resistant Candida auris is Susceptible to Salivary Histatin 5 Killing and to Intrinsic Host Defenses | Q46257698 | ||
| Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates | Q46835624 | ||
| Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates | Q46919709 | ||
| Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model | Q47245367 | ||
| Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics | Q47741040 | ||
| Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis | Q48143674 | ||
| Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans | Q50060258 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Lacticaseibacillus casei | Q139777 |
| Lacticaseibacillus paracasei | Q1799829 | ||
| Candida auris | Q26816853 | ||
| P304 | page(s) | 397 | |
| P577 | publication date | 2020-08-04 | |
| P1433 | published in | Frontiers in Cellular and Infection Microbiology | Q27724376 |
| P1476 | title | The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris | |
| P478 | volume | 10 |
Search more.